论文部分内容阅读
生物利用度(Bioavailability)是生物药剂(Biopharmaceuties)的一项重要参数。生物药剂国际会议正在制订统一定义,目前较一致的定义是:服用药剂后所测得药剂中主药到达体循环的相对数量与在体循环中出现的相对速率。根据定义,生物利用度有二项参数:(1)生物利用度的程度(EBA),是指与比参品相比,试样中被吸收药物总量的相对比值,即相对百分数;(2)生物利用度的速率(RBA),是指与比参品相比,从试样中被吸收药物速率的相对比值,用血药浓度峰值(C_(tp))与峰期(t_p)来表示。临床上早在1960年就发现药剂的疗效不
Bioavailability is an important parameter of Biopharmaceuties. The International Conference on Biopharmaceuticals is developing a harmonized definition that is currently more consistently defined as the relative amount of primary drug reaching the systemic circulation and the relative rate seen in the systemic circulation measured after administration of the agent. By definition, bioavailability has two parameters: (1) The degree of bioavailability (EBA), which is the relative percentage of the total amount of drug absorbed in the sample compared to the sample, ie, the relative percentage; (2) ) The rate of bioavailability (RBA) is the relative ratio of the rate of drug absorption from the sample compared to the reference product, expressed as the peak plasma concentration (C_ (tp)) and peak period (t_p) . Clinically as early as 1960 found that the efficacy of the drug does not